Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31624491 | 0.72 | ADORA1 (0.60) | ADORA1ADORA2ATSHRCA5AKDM4E | |
| SCHEMBL30680914 | 0.70 | ADORA1 (0.57) | ADORA1ADORA2ATSHRCA5AKDM4E | |
| SCHEMBL7978388 | 0.69 | ADORA1 (0.61) | ADORA1ADORA2ATSHRCA5AKDM4E | |
| SCHEMBL23474014 | 0.67 | DHFR (0.50) | ADORA1ADORA2AKDM4ELMNAHSD17B10 | |
| SCHEMBL11589180 | 0.67 | ADORA1 (0.58) | ADORA1ADORA2ACA5AKDM4EMAPK14 | |
| SCHEMBL11591796 | 0.66 | ADORA1 (0.53) | ADORA1ADORA2ATSHRCA5AKDM4E | |
| SCHEMBL11592378 | 0.66 | ADORA1 (0.53) | ADORA1ADORA2ACA5AKDM4EBLM | |
| SCHEMBL799183 | 0.65 | CYP1A2 (0.59) | KDM4ELMNACYP1A2PKMCYP2C19 | |
| SCHEMBL25899176 | 0.65 | DHFR (0.44) | TSHR | |
| SCHEMBL12192591 | 0.64 | CYP3A4 (0.41) | TSHRKDM4ECYP1A2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322779-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-12 | — | — | US | disclosed |
| EP-4208166-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2023-07-12 | — | — | EP | disclosed |
| WO-2022049521-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2768506-A2 | COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES | GlaxoSmithKline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| CN-103957910-A | Compounds and methods for enhancing innate immune responses | GLAXOSMITHKLINE LLC | 2014-07-30 | — | — | CN | disclosed |
| WO-2013059559-A2 | COMPOUNDS AND METHODS FOR ENHANCING INNATE IMMUNE RESPONSES | GLAXOSMITHKLINE LLC (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322779-A1 | IMIDAZONAPHTHYRIDINES AND IMIDAZOPYRIDOPYRIMIDINES AS IFNAR2 AGONISTS FOR TREATING SARS-COV-2 INFECTIONS | IFNAR1, IFNG, EIF2AK2 | ADORA1 943/4885ADORA2A 147/4885TSHR 514/4885 |
| US-20140249143-A1 | Compounds And Methods For Enhancing Innate Immune Responses | MYD88, IRF3, MAVS | ADORA1 764/4885ADORA2A 504/4885TSHR 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.